每经记者|金喆 每经编辑|张益铭当地时间6月2日,在2025年美国临床肿瘤学会(ASCO)年会上,百时美施贵宝(BMS)宣布拟斥资最高达111亿美元与BioNTech合作,共同开发并商业化一款肿瘤药——BNT327。这是一种靶向PD-L1和VEGF-A的双特异性抗体药物,用于治疗多种实体瘤。与此前双抗药物领域的交易相似,BNT327的核心资产源自中国公司,是BioNTech去年通过收购中国...
Source Link每经记者|金喆 每经编辑|张益铭当地时间6月2日,在2025年美国临床肿瘤学会(ASCO)年会上,百时美施贵宝(BMS)宣布拟斥资最高达111亿美元与BioNTech合作,共同开发并商业化一款肿瘤药——BNT327。这是一种靶向PD-L1和VEGF-A的双特异性抗体药物,用于治疗多种实体瘤。与此前双抗药物领域的交易相似,BNT327的核心资产源自中国公司,是BioNTech去年通过收购中国...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.